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Abstract

SYMPTOM CLUSTERS IN LUNG CANCER PATIENTS
By Debra Rattican, PhD, RN
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy at Virginia
Commonwealth University.

Virginia Commonwealth University, 2012
Major Director: Debra E. Lyon, PhD.
Professor and Chair
Family and Community Health Nursing

The purpose of the study was to examine selected relationships
among symptoms common to individuals with lung cancer. The
specific aims were:
1) To examine the relationship between the symptoms of dyspnea
and anxiety in patients with lung cancer.
2) To examine the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer.
3) To examine the correlation between functional ability and
quality of life in patients with lung cancer.
4) To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,

fatigue, pain) in patients with lung cancer and patients’
functional ability.
5) To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer and patients’
quality of life.
Data were gathered through online survey and analyzed using
descriptive, correlation, principal component analysis,
exploratory factor analysis, and forward stepwise regression
techniques.
A strong positive correlation was found between dyspnea and
anxiety (both anxiety in general and anxiety at the time the
survey was completed.
While results of this study cannot provide conclusive
evidence of the existence of a symptom cluster composed of
depressive symptoms, fatigue, and pain, the results are
consistent with other studies in this area. Significant positive
correlations among these three symptoms indicate that this is a
possible symptom cluster experienced by lung cancer patients in
general.
This study provides preliminary data on how these symptoms
are related and how they affect functional ability, or the
ability to perform routine activities of daily living (ADLS) and
instrumental activities of daily living (IADLS), and quality of

2

life in patients with lung cancer. Further study is needed on to
better understand the symptom experience of these individuals in
order to develop robust interventions targeting effective
symptom management.

3

Chapter 1
INTRODUCTION
Lung cancer is the second most prevalent cancer in the
United States in both men and women and the greatest cause of
cancer mortality worldwide, killing more individuals than
breast, prostate, colon, and pancreatic cancer combined1. Major
advances in treatment over the past decade have led to a 50% to
70% improvement in the median survival times of patients with
lung cancer1. In spite of advances in chemotherapy, surgery, and
radiation therapy, the five-year survival rate for lung cancer
remains at only 16%. The 5-year survival rate is 49% for cases
detected when the disease is still localized; however, only 16%
of lung cancer cases are diagnosed at this early stage

1

. Two out

of 3 individuals are diagnosed with extensive spread of the
cancer beyond one lung when first diagnosed, meaning that a cure
with radiation and/or chemotherapy is very unlikely. Still, 42%
percent of these individuals will still be alive one year after
diagnosis, and 27% will survive for at least 2 years after
diagnosis

1

. In light of these statistics, symptom management is

of great importance in the nursing care of patients with lung
cancer.
For individuals with lung cancer, dyspnea is one of the
most distressing symptoms. Although dyspnea affects from 60% to
90%

2

of patients with lung cancer, dyspnea has been understudied

4

compared to other cancer symptoms, and there has been relatively
limited research on dyspnea in patients with lung cancer,
although it affects the majority of this population
defined as “an uncomfortable awareness of breathing”

3

. Dyspnea is
2

. Dyspnea

is a subjective sensation that does not necessarily correlate
with the degree of respiratory compromise. Studies have shown a
positive correlation between dyspnea and anxiety4 and that
anxiety can influence the intensity of dyspnea3;5. Dyspnea is a
complex symptom with both psychological and physiological
components6-8. Pulmonary function (PF) tests have shown variable
degrees of correlation with the intensity of dyspnea in noncancer populations3, but there has been little concurrent study
of dyspnea measures with PF

measures such as spirometry and

other variables known to affect perceived dyspnea, such as
anxiety in the lung cancer population.

In persons with lung

cancer, dyspnea has been shown, in both qualitative and
quantitative studies, to have a significant negative impact on
daily activities

9

and thereby, on quality of life.

There is a growing body of evidence that symptoms may
cluster or co-occur in a systematic way in individuals with
cancer

10

and adversely affect quality of life. While there are

several strategies used for identifying symptom clusters, a
prominent cluster composed of the symptoms of depression,
fatigue and pain has been identified in persons with different

5

types of cancer across the disease spectrum

11-13

. These symptoms

may be caused by the disease, its treatment, or both. Depression
is a symptom commonly experienced by people with cancer and is
known to exacerbate pain and fatigue

12-14

. Fatigue has been

described as the most frequent symptom experienced by cancer
patients15-21 and has been shown to interfere with functional
ability and quality of life15;22. There is evidence that the
incidence of pain in lung cancer patients may be as high as
100%23 and that patients’ experience of pain is worse in the
presence of multiple symptoms24.
Despite the importance of symptom management in patients
with lung cancer, there has been little research into multiple
distressing symptoms that have known adverse effects on patient
outcomes of functional ability and quality of life. The majority
of studies on cancer symptoms have examined individual
symptoms15;25;26. Relationships among multiple symptoms and patient
outcomes have not been well described10;15;25. The proposed study
adopts the Theory of Unpleasant Symptoms (TOUS) to guide the
research

27

into examining the relationships among dyspnea,

pulmonary function (as measured by spirometry), and anxiety;
among dyspnea, anxiety, and symptom cluster components
(depression, fatigue, pain); and among dyspnea, anxiety, symptom
cluster components (depression, fatigue, pain) and patient
outcomes of functional ability and quality of life in lung

6

cancer patients.

While dyspnea has been identified by the

Oncology Nursing Society as a priority area related to symptom
management28, and is known to occur in most patients with lung
cancer29;30, little is known about the relationship of dyspnea, a
multidimensional symptom, with objective measures such as
spirometry; with anxiety; or with other common cancer-related
symptoms including depression, fatigue, and pain, that have been
identified as a possible cluster in lung and other cancers12;13.
Research is needed to further elucidate the potential
relationships among these variables in order to develop tailored
symptom-management interventions for dyspnea and co-occurring
symptoms.
Therefore, the specific aims of the proposed study are:
1. To examine the relationships among the symptoms of dyspnea,
pulmonary function (spirometry), and anxiety in patients with
lung cancer.
2. To examine the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer.
3. To examine the correlation between functional ability and
quality of life in patients with lung cancer.
4. To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,

7

fatigue, pain) in patients with lung cancer and patients’
functional ability.
5. To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer and patients’
quality of life.
This proposal addresses the National Cancer Institute’s

31

mission to reduce cancer burden and, specifically, their
objective to improve quality of life for cancer patients through
efforts to understand the biologic, physical, psychological and
social mechanisms and their interactions that lead to disease or
treatment sequelae. Dyspnea is a priority, yet understudied,
area related to symptom management28. The Oncology Nursing
Society has identified symptom clusters and their associated
outcomes as a priority topic on their research agenda

28

. A

better understanding of how these symptoms are related would
give important insight necessary to the future development of
symptom management interventions to target multiple concurrent
symptoms to achieve optimum outcomes and improved quality of
life for these patients. The proposed study will advance this
understanding and provide preliminary data for the development
of interventional studies targeting symptom management
strategies for persons with lung cancer.

8

Specifically, this study will provide preliminary data
regarding the important symptom of dyspnea in lung cancer. There
has been little examination of the objective (spirometry) vs.
subjective (anxiety related) components of dyspnea in lung
cancer. This knowledge is needed to better design interventions
to manage the symptom of dyspnea. The proposed study will also
further our knowledge of the relationships among dyspnea and
other commonly identified symptoms in patients with cancer that
have been identified as components of a symptom cluster and
provide a better understanding of how these common distressing
symptoms are related and how they affect patient outcomes of
functional status and quality of life in patients with lung
cancer. Knowledge gained from this study may inform the
development of robust interventions to prevent and manage the
symptom cluster (depression, fatigue, pain) and improve quality
of life for lung cancer survivors.
Effective symptom management is vitally important for
individuals with lung cancer, a population characterized by
excessive symptom burden and limited survival time. Lung cancer
and its treatment impose numerous symptoms on patients. Most of
those symptoms have been studied in isolation and there has been
only limited research aimed at clarifying how the various
dimensions of the symptom experience might be related to each
other as a symptom cluster, particularly in patients with lung

9

cancer. Specific aims of this cross-sectional study are: 1) to
examine the relationships among the symptoms of dyspnea,
pulmonary function (spirometry), and anxiety in patients with
lung cancer; 2) to examine the relationship among the symptoms
of dyspnea, anxiety,

and symptom cluster components (depressive

symptoms, fatigue, pain) in patients with lung cancer; 3) to
examine the correlation between functional ability and quality
of life in patients with lung cancer; 4) to explore the
relationships among the symptoms of dyspnea, anxiety, and
symptom cluster components (depressive symptoms, fatigue, pain)
in patients with lung cancer and patients’ functional ability;
and 5) to explore the relationships among the symptoms of
dyspnea, anxiety, and symptom cluster components (depressive
symptoms, fatigue, pain) in patients with lung cancer and
patients’ quality of life. The proposed study will contribute to
our understanding of the underlying mechanisms of a proposed
cluster of symptoms (depressive symptoms, fatigue, pain) in lung
cancer patients and the potential synergistic effects among
these symptoms, and to development of an operational definition
of a symptom cluster in this population. Specifically, this
study will provide preliminary data on how these symptoms are
related and how they affect patient outcomes. Knowledge gained
may lead to the development of robust interventions to prevent

10

and manage the symptom cluster and improve the quality of life
for lung cancer survivors.

11

Chapter 2
REVIEW of the LITERATURE
Lung cancer typically forms in the tissues of the lung,
usually in the cells that line the air passages. The two main
types of lung cancer are small-cell lung cancer (SCLC), also
called oat cell cancer, and non-small cell lung cancer (NSCLC).
It is estimated that, for the two types combined, there will be
215,020 new cases in 2008

32

. Lung cancer is the 2nd most

diagnosed cancer in both men and women (after prostate and
breast, respectively) and the number one cause of death due to
cancer in both men and women. Two out of three patients are not
diagnosed until after the cancer has spread beyond the original
site, making a cure very unlikely
priority

33;34

33

and symptom management a

. Lung cancer is a disease of multiple symptoms,

including dyspnea, anxiety, depression, fatigue, and pain.
Improving these symptoms can significantly improve functional
ability and quality of life for patients with lung cancer

35;36

.

THEORETICAL MODEL
The proposed study adopts the Theory of Unpleasant Symptoms
(TOUS) (Figure 1) to provide the theoretical underpinnings for
the proposed research. The model suggests that several symptoms
can occur together and that physiological, psychological, and
situational factors may influence the symptom experience. The
theory has three major components; the symptoms, influencing

12

factors, and consequences of the symptom experience

27

. The

symptoms are the central focus of the model and, when multiple
symptoms co-occur, the experience is potentially multiplicative
rather than additive. That is, two or more symptoms occurring at
the same time are likely to catalyze each other.

For example,

pain seems worse when accompanied by fatigue; and may be
disproportionately even more severe when both fatigue and
depressive symptoms are experienced concurrently with it. The
model proposes that, through a feedback mechanism, there are
ongoing reciprocal influences among the symptoms, the
influencing factors, and the consequences of the symptom
experience

27

. For example, the cluster of depressive symptoms,

fatigue, and pain have a negative impact on functional ability.
This loss of functional ability may, in turn, increase the
intensity and duration of depressive symptoms. Ultimately, this
synergy has an enormous negative impact on quality of life. At
this point, we are not testing the theory, but using the TOUS to
guide the theoretical relationships among the variables of the
study. The TOUS provides a theoretical guide for the research
model (Figure 2) developed for the proposed study.

13

Figure 1. Updated version of the middle-range theory of
unpleasant symptoms 27

Common Symptoms in Persons with Lung Cancer
Dyspnea
Dyspnea has been defined as an uncomfortable awareness
or sensation

5

2;37;38

of breathing, or the experience of difficult and

labored breathing

4

. The American Thoracic Society

39

defines

dyspnea as a multifactorial subjective experience that derives
from interactions among physiological, psychological, social,
and environmental factors. This experience may induce secondary
physiological and behavioral responses

39

.

Dyspnea is

experienced by 29-74% of the general cancer population

4

. Graves

et al. report a prevalence of 52.7% in their study of lung
cancer patients

29

. Joyce et al. report that prevalence of

dyspnea in the lung cancer population may be as high as 87%,
with no significant difference based on stage

14

30

, and with a

reduction in functional ability as a frequent consequence.
Dyspnea occurs in all stages of the disease and can be severe
even in patients with early-stage disease. It has been shown to
be positively correlated with pain and negatively correlated
with quality of life

4

. The relationship between pain and dyspnea

is, at present, a matter of some controversy. It is unknown
whether pain worsens dyspnea, dyspnea worsens pain, or they
coexist with no presumed causal relationship

5

.

There are conflicting reports on whether dyspnea is
significantly correlated with pulmonary dysfunction

5

.

It has

been reported that dyspnea in cancer patients is associated with
abnormal vital capacity and maximum inspiratory pressure
Heyes-Moore et al.

40

2;3;33;37

.

did not find spirometric indices to be a

reliable guide to subjective reports of dyspnea. Oncologists
generally assume that dyspnea is secondary to tumor mass or
metastasis and rarely perform pulmonary function tests

2

. Despite

its high prevalence, there is a lack of understanding about the
pathophysiology and management of dyspnea, and it remains one of
the most refractory symptoms of individuals with advanced or
terminal cancer, regardless of cancer site

5

. Surgical and

radiation treatments for early stage lung cancer can lead to
life-long dyspnea, leaving those who are most likely to be cured
with a debilitating symptom that reduces their quality of life
Dyspnea affects physical, psychological, and social aspects of

15

4

.

patients’ lives

6;38

. Individuals with cancer experience

difficulty in performing activities of daily living, they often
feel that they are a burden to their families, and social
interaction is often restricted

38

because of dyspnea.

Improvements in spirometers have made it possible to measure
pulmonary function in clinics and

objective measures of

pulmonary function, particularly spirometry, have been
correlated with functional ability and quality of life in
patients with chronic lung disease33. Still, the relationship of
pulmonary function to these patient outcomes has not been fully
evaluated in lung cancer patients33 and these innovations have
not yet been integrated into symptom management of dyspnea in
this population. Identifying a relationship between its
objective and subjective components will contribute to a better
understanding of the physiological and psychological aspects of
perceived dyspnea and its relationship to other symptoms.
Anxiety
Anxiety, along with dyspnea, pain, fatigue, and depression,
has been shown to be predictive of distress in cancer patients.
Anxiety is particularly important in lung cancer.

Individuals

with lung cancer report higher levels of psychological distress
than individuals with other cancer diagnoses

29

. In their study

to determine the rates and predictors of distress in a sample of
patients being seen in a multidisciplinary lung cancer clinic,

16

Graves et al. found that 62.4% of patients reported a clinically
significant level of anxiety

29

. In the same study, 65.4% of

patients reported fatigue, 64.9% reported pain, 52.7% reported
difficulty breathing, and 49.3% reported depression at
clinically significant levels. Anxiety has been shown to be
strongly correlated with dyspnea in lung cancer patients,
however, that correlation is difficult to interpret, since
anxiety may either contribute to or be caused by dyspnea

3

. More

research is needed to clarify the complex relationships among
anxiety and dyspnea, and anxiety with the cluster components of
depressive symptoms, fatigue, and pain in this population.
Symptom Clusters
Individuals with lung cancer, whether newly diagnosed or
advanced, suffer more severe symptoms than those with other
cancers at a similar stage in their disease

41

. These patients

often experience multiple symptoms concurrently

10;24-26;33;41-55

,

which can result in poorer patient outcomes and have a more
negative effect on the individual’s quality of life than any
single symptom alone. These symptoms may be disease-related,
treatment-related, or both

10;45;47;49;53-58

. While there is not yet a

universally accepted definition of a symptom cluster

46

, nor a

consensus as to whether two symptoms can constitute a symptom
cluster, the generally accepted definition is that a symptom
cluster is the concurrent presence of two (or three) or more

17

symptoms that are related to each other in some way
10;13;24;49;50;55;58

.

The vast majority of symptom management research to date is
embedded in a single symptom framework, focusing on an
individual symptom

25;26;45;47;53;55;56;59

, such as pain or fatigue, or

on symptoms, such as depression or anxiety, that correlate with
a single symptom

24;47;56

. While this has greatly advanced the

state of the knowledge regarding symptom management, it may not
be sufficient to guide clinical practice when patients present
47;56

with multiple concurrent symptoms

. The gap between the

paradigm guiding research and the ‘real world’ symptom
experience of individuals with lung cancer limits the growth of
our knowledge base regarding effective symptom management. Our
knowledge base is lacking in terms of the relationships among
the symptoms experienced by patients with cancer

60

. The symptom

experience may worsen with the addition of each new symptom
the symptoms may interact

59

27

;

; or there may be one symptom that

makes all of the others seem worse

60

.

Research into the concept of symptom clusters is in its
infancy

26;49

and there are many questions left to be answered.

One of the first studies to investigate symptoms as a cluster
examined fatigue, pain, and sleep disturbance
study patients with lung cancer

41

47

, but did not

. Much of the research that has

been done on symptom clusters in individuals with cancer has

18

examined heterogeneous groups, rather than focusing on a
specific type of cancer

60

. A literature review by Fan, et al.

49

revealed only 2 studies that included only lung cancer patients.
The different methodologies used in those 2 studies made it
impossible to explore a common symptom cluster in this
population.
Symptom cluster components
Because symptoms including depression, fatigue, pain, and
sleep disturbances occur concurrently in persons with cancer,
there is a movement toward examining a “cluster” of co-occurring
symptoms instead of focusing on individual symptoms25. Symptom
cluster is a relatively new concept in the cancer literature,
with a working definition suggesting that symptom clusters are
composed of at least two58 or three interrelated symptoms24.
Although the study of symptom clusters has only recently evolved
in the cancer literature, a prominent group of symptoms
including depressive symptoms, fatigue, and pain has been
identified in persons with different cancers and at different
stages, and the symptoms have been consistently associated with
poorer QOL. Although there are probably multiple symptom
clusters that have not yet been identified or empirically
validated, the cluster of depressive symptoms, fatigue, and pain
is particularly important because it does not appear to be
cancer type- or stage-specific and has been noted both in

19

patients with cancer undergoing treatment and in cancer
survivors61.
Depressive symptoms. At least 10%-25%13 and possibly as many
as 50%62 of patients with cancer experience depression at some
point during the course of the disease and its treatment.
Depression may be a response to diagnosis and decrease over
time, however, in many patients the depression persists and
hampers disease management and symptom control. Persistent
depression has been shown to decrease compliance with treatment
and to reduce survival rate62. In their study to map the
trajectory of depression and its components in a sample of 860
patients, Stommel, Kurtz, Kurtz, Given & Given found that lung
cancer patients had higher depression scores that those with
cancers of the breast, colon and prostate. Their findings
indicate that stage of cancer does not appear to affect
depressive symptomotology62. Patients have reported that
depressive symptoms; which include feelings of sadness,
loneliness, hopelessness; loss of appetite; and low self-esteem;
are among the most distressing symptoms of cancer and these
symptoms may be correlated with pain severity, functional
ability, and quality of life14. A better understanding of these
relationships will provide the basis for improved symptom
management for these patients.

20

Fatigue.

Cancer-related fatigue (CRF) is the most

prevalent and disruptive consequence of cancer and cancer
treatment
100%

63

16-21

, affecting over 75%

21

, and possibly as many as

of patients undergoing chemotherapy or radiation therapy.

Graves et al. report a prevalence of 65.4% in their study of
lung cancer patients

29

. Fatigue associated with cancer and its

treatment differs from the acute or chronic fatigue experienced
by the general population after normal exertion, in that it has
been reported as a more intense and more disruptive lack of
energy that is not attenuated by rest. Empirical evidence
suggests that CRF is present before, during, and after treatment
64

. Debilitating fatigue is reported by persons with all types of

cancer; in early to advanced stages; and receiving chemotherapy,
radiation therapy, hormonal therapy, biologic therapy, bone
marrow or stem cell transplant, or combined modality treatments
65

. Evidence suggests that persons with lung cancer experience

more severe fatigue than those with other types of cancer at a
similar stage

41;66

. Cancer survivors continue to report fatigue

as a significant problem months to years after treatment is
complete

15;16

. Bower et al.

67

, in a survey of breast cancer

survivors, found that one third of the subjects reported severe
fatigue three years after their diagnosis. While fatigue in
healthy people is a normal response to physical or psychological
stress, patients with cancer describe the fatigue they

21

experience as chronic, distressing, and life and activitylimiting throughout the day

22

. Despite its prevalence, there is

limited empirical evidence to clarify the underlying mechanisms
involved in the pathophysiology of CRF. Proposed mechanisms
include biochemical factors, such as increased pro-inflammatory
cytokine production, endocrine changes, such as serotonin
dysregulation

68

, and sleep quality

69

.

Pain. Lung cancer is one of the most common cancers to
cause pain. Published reports indicate that as many as 50% of
patients with SCLC and 65% of patients with NSCLC suffer pain

70

.

Other studies place estimates of the frequency of lung cancer
pain between 14% and 100%

23;29

. Multiple sites of pain have been

reported by lung cancer patients, with the most common sites
being the chest wall and the lumbar spine

30

. Because it is so

prevalent in patients with lung cancer, it is imperative that we
increase our understanding of pain in the context of a symptom
cluster.
Patient Outcomes
Functional Ability
The functional consequences of symptom burden in persons
with lung cancer are severe.

In a study of 171 lung cancer

patients, Tanaka, et al34 found that dyspnea and pain interfered
with at least one daily activity (>50% of patients, 40% of
patients, respectively). Numerous studies have shown that

22

dyspnea causes significant interference with the ability of
persons with lung cancer to participate in their usual physical
activities

2;6;9;33;34

of patients’ lives

. The pain of lung cancer affects all aspects
36

. The Fatigue Coalition determined that CRF

causes substantial functional and psychological impairment, and
is rarely discussed or treated

71

. Studies have shown that women

diagnosed with breast cancer report a decrease in functional
ability accompanying increased fatigue and sleep disturbance
even before the start of their chemotherapy

64

. The effect of CRF

on the functional ability of cancer survivors may continue well
after treatment is complete, altering daily routines and
preventing a normal life

71

. These individuals experience

difficulties in accomplishing basic activities of daily living
(ADLs) and instrumental activities of daily living (IADLs), such
as general household chores, social activities, running errands,
preparing food, and meeting the needs of their families. The
limitations on physical, emotional, mental, and social
activities contribute to decreased quality of life for persons
with lung cancer.
Quality of Life
The World Health Organization (WHO) defines Quality of Life
as an individual’s perception of their position in life in the
context of the culture and value systems in which they live and
in relation to their goals, expectations, standards and concerns

23

72

. As advancements in cancer treatment result in patients with

cancer living for longer periods of time, it becomes even more
important that we pay attention to patients’ quality of life
73;74

. Quality of life is an abstract concept that is perceived

differently by each individual
over time

75-77

75

and that perception can change

. When cancer patients can no longer participate in

activities they enjoy, their quality of life is adversely
affected

63

. Both physical and mental aspects of quality of life

are affected by cancer and its consequences

78

. Studies have

shown that cancer patients report significantly lower overall
quality of life, especially in the domains of physical and
social functioning

73

of functional ability

than healthy controls. Fatigue, pain, loss
36

and depression13;14 all contribute to

diminished quality of life in persons with lung cancer. As the
rate and duration of cancer survival continues to improve,
attention to this patient outcome may be a more important
consideration than attention to such cancer outcomes as rate and
duration of response to treatment79.

24

Chapter 3
RESEARCH DESIGN and METHODS
This study used a cross-sectional design to address the
following specific aims in patients with lung cancer:
1. To examine the relationships among the symptoms of dyspnea,
pulmonary function (spirometry), and anxiety in patients with
lung cancer.
2. To examine the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer.
3. To examine the correlation between functional ability and
quality of life in patients with lung cancer.
4. To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer and patients’
functional ability.
5. To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer and patients’
quality of life.
Variables examined in the study are summarized in Table 1.
The model (Figure 2) reflects the multifactorial manifestations
of multiple concurrent symptoms in persons with lung cancer and
the physiological and psychological factors involved in the
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experience of a symptom cluster. Anxiety has been shown to be
strongly correlated with dyspnea in lung cancer patients;
however, that correlation is difficult to interpret, since
anxiety may either contribute to or be caused by dyspnea

3

. More

research is needed to examine the relationship of dyspnea with
objective measures such as spirometry and to compare the
correlation between dyspnea, spirometric measures and anxiety.
This will provide a better understanding of the relationship
between pulmonary function, the psychological aspect of anxiety
and dyspnea. This will help to clarify the objective/subjective
aspects of dyspnea, which will lead to future targeted
interventions.
Table 1. Components of the Research Model and Study Variables
Physiologic Factors
Stage of cancer
Cancer treatments
Age
Gender
Co-Morbidities
Pulmonary
Function

Symptoms
Dyspnea
Anxiety
Depressive
symptoms
Fatigue
Pain
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Patient Outcomes
Functional ability
Quality of life

Symptoms

Physiologic factors
Stage of cancer
Cancer treatments
Age
Gender
Co-morbidities
Pulmonary function

Dyspnea
Anxiety
Symptom cluster components
▪Depressive symptoms
▪Fatigue
▪Pain
Symptom
Experience
with
Lung Cancer

Patient Outcomes
Functional ability
Quality of life

Figure 2. Research Model

Setting
The study was conducted at the Virginia Commonwealth
University School of Nursing and the Virginia Commonwealth
University Health System- Massey Cancer Center in Richmond,
Virginia, one of only 63 National Cancer Institute – designated
Cancer Centers in the United States. Massey is also designated
as a National Cancer Institute Minority-based Clinical Oncology
Program; 40 percent of its patients are minorities. Descriptive
statistics of the number of patients receiving treatment, by
gender and race, for lung cancer are summarized in Table 2 (2006
VCUHS-MCC data).
Additionally, data were collected online via a survey
posted on Survey Monkey. Five organizations (American Cancer
Society, Joan Gaeta Lung Cancer Foundation, Kate MacIntyre
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Foundation, Lung Cancer Alliance, and National Lung Cancer
Partnership) agreed to post the online recruitment advertisement
and link to the survey on their web sites.

Table 2. Patients Receiving Treatment for Lung Cancer by Gender
and Race (2006 VCUHS-MCC data)

Black
32

Females
White
66

Other
4

Black
43

Males
White
67

Other
4

Total
216

Sample
The sample of 51 participants was recruited through the
online sites. There were no consenting participants enrolled
from the Massey Cancer Center Chest Tumor Clinic. Male and
female adults (aged 21 years and older) from all racial/ethnic
backgrounds were recruited. Inclusion criteria were: age 21
years or older; histological confirmation of lung cancer; able
to read, speak, and understand English. The inclusion criteria
for this descriptive study did not define an a priori level of
symptom severity needed for eligibility for the study; it is
likely, based on the literature, that most patients will have
measurable levels of most symptoms. Exclusion criteria were:
concurrent severe or uncontrolled asthma as defined by the
American Academy of Allergy, Asthma and Immunology; brain
metastasis; active psychosis or organic brain damage interfering
with ability to provide informed consent; post-surgical patients
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less than 2 weeks off of supplemental oxygen at the time of data
collection; completion of chemo- or radiation therapy less than
4 weeks prior to data collection; acute medical problem or
emergency requiring immediate attention. Inclusion and exclusion
criteria are summarized in Table 3.
Table 3. Inclusion and Exclusion Criteria
Inclusion
Age 21 or older

Exclusion
Concurrent severe or uncontrolled asthma
as defined by the American Academy of
Allergy, Asthma and Immunology
Brain metastasis
Active psychosis or organic brain damage
interfering with ability to provide informed
consent
Post surgical patients less than 2 weeks off
of supplemental oxygen at time of data
collection
Completion of chemotherapy or radiation
therapy less than 4 weeks prior to data
collection
Acute medical problem or emergency
requiring immediate attention

Histological confirmation of lung cancer
Able to read, speak, and understand
English

The author acknowledges that, due to the nature of data
collection via anonymous online survey, the sample may include
participants who would have been excluded with researcher
screening for exclusion criteria.
Power analysis was performed using nQuery Advisor 6.0 using
the predictor variables (dyspnea, anxiety, depressive symptoms,
fatigue, pain) and the outcome variables (functional ability and
quality of life), assuming that 20% of the variance can be
accounted for by the predictor variables. Power was found to be
80% for the proposed sample size. Post hoc power analysis showed
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71% power with the sample of 51 participants. Data collection
occurred over a 16 month period of time.
Methods
The measurement tools used for the key variables are described
below and summarized in Table 4.
Table 4. Key Study Variables and Their Measurement
Variable
Demographics

Domain
Physiological

Clinical
Characteristics

Physiological

Dyspnea
Fatigue
Pain
Depressive
symptoms
Anxiety
Functional ability
Quality of life

Psychological
Psychological
Psychological
Psychological
Psychological
Outcomes
Outcomes

Measure
Age, Gender, Race/ethnicity,
Smoking history, medical co-morbidities
Stage and histological type of lung cancer, past and current
treatments for lung cancer, time since diagnosis,
Pulmonary function
Cancer Dyspnea Scale (CDS)
Brief Fatigue Inventory (BFI)
Brief Pain Inventory (BPI)
Center for Epidemiologic Studies Depression Scale (CESD)
The State-Trait Anxiety Inventory (STAI)
Duke Activity Status Index (DASI)
Functional Assessment of Cancer Therapy-Lung Scale
(FACT-L)

Dyspnea was measured using the Cancer Dyspnea Scale (CDS).
The CDS is a 12-item scale that measures the multidimensional
nature of dyspnea on a 5-point Likert scale. The CDS has shown
reliability (Cronbach’s α = 0.86)and validity in use with cancer
patients

80

. Average completion time of the CDS is less than

three minutes

80

.

Anxiety was measured using The State-Trait Anxiety Inventory
(STAI). The STAI is a 40-item measure that assesses anxiety at
the time of answering the questionnaire (state: STAI-s) and the
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general tendency to be anxious (trait: STAI-t). The STAI has
been widely used and has demonstrated reliability (Cronbach’s α =
0.88)and validity in the study of anxiety across a variety of
medical populations, including persons with cancer

81

.

Estimated

time for completion of the self-report instrument is 5 minutes.
Depressive symptoms were measured using the Center for
Epidemiologic Studies Depression Scale (CES-D). This is a 20item scale that assesses depressive symptomatology in the
domains of: depressed mood (7 items); absence of well-being (4
items); somatic symptoms (7 items); and interpersonal relations
(2 items). This instrument has been used in many studies
involving cancer patients and has been found to be a valid and
reliable (Cronbach’s α = 0.89) measure of depressive
symptomotology in this population62;82. Estimated time for
completion of the self-report instrument is 3 minutes.
Fatigue was measured using the Brief Fatigue Inventory (BFI).
The BFI is a 9-item scale that measures physical and
psychological aspects of fatigue on an 11-point Likert scale.
The first 3 questions evaluate present, overall, and worst
fatigue, respectively. The 4th question asks patients to
characterize the level of interference caused by their fatigue
during the past 24 hours according to the following 6
categories: general activity, mood, walking ability, normal
work, relations with other people, and enjoyment of life. The
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BFI has demonstrated reliability (Cronbach’s α = 0.96) and
validity in men and women with cancer

83

. Estimated time for

completion of the self-report instrument is 2 minutes.
Pain was measured using the short form of the Brief Pain
Inventory (BPI). The BPI (short form) is a 9-question selfreport instrument consisting of 11 numeric scales based on the
impact of pain on the patients general activity, mood, ability
to walk, work, relationships, sleep, and enjoyment of life. The
BPI addresses the sensory, affective, and evaluative qualities
of pain in the following domains: experience of pain, location,
intensity, pain medications, pain relief, and interference with
daily activity. This tool has demonstrated reliability
(Cronbach’s α = 0.97) and validity
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including studies of cancer patients

in previous studies,
85;86

. Estimated time for

completion of the self-report instrument is 2 minutes.
Functional Ability was measured using the Duke Activity
Status Index (DASI). The DASI is a 12-item yes/no questionnaire
that quantifies functional capacity from a patient-focused
perspective. It has been found to be a valid instrument when
compared to measured physiologic indices of functional capacity.
The DASI significantly correlates with total walk distance in
the 6-minute-walk test (6MWT) (r= 0.53, p<.0001)87. The DASI was
also found to be significantly correlated with peak oxygen
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uptake (r= 0.81, p<.0001)88. Estimated time for completion of the
DASI is less than 5 minutes.
Quality of Life was measured using the Functional
Assessment of Cancer Therapy – Lung scale (FACT-L). The FACT-L
(version 4) is a 36-item self-report instrument designed to
assess quality of life in individuals with lung cancer. It
consists of 4 subscales assessing general domains of healthrelated quality of life (the core FACT-G) and one that measures
issues specific to lung cancer. The general subscales are:
physical well-being (7 items), social/family well-being (7
items), emotional well-being (6 items), and functional wellbeing (7 items). The lung cancer subscale consists of 9 items.
The FACT-L and all of its subscales have been thoroughly tested
and found to be reliable (Cronbach’s α = 0.89), valid, and
sensitive to change in lung cancer populations

35;89-91

. Estimated

time for completion of the self-report instrument is 5 minutes.
Item burden for self-report instruments is summarized in
Table 5.
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Table 5. Item Burden for Self-Report Instruments
Number
of
Items
Cancer Dyspnea Scale (CDS)
12
State-Trait Anxiety Inventory (STAI)
40
Center for Epidemiologic Studies Depression Scale (CES-D)
20
Brief Fatigue Inventory (BFI)
9
Brief Pain Inventory (BPI)
9
Duke Activity Status Index
12
Functional Assessment of Cancer Therapy-Lung (FACT-L)
36
Totals
138
Instrument

Minutes
To
Complete
3
5
3
2
2
5
5
25

Procedures
IRB approval.

Approval by the Institutional Review Boards

(IRBs) was obtained for the proposed study.

Virginia

Commonwealth University (VCU) was the primary review board.
Approval was also obtained from the IRBs at Massey Cancer Center
(MCC) and the General Clinical Research Center (GCRC).
Recruitment and enrollment.

The physicians and nurses at

the Massey Cancer Center (MCC) provided a clinical link for the
recruitment of in-person participants into the study. Any
questions related to eligibility were reviewed with the
appropriate member of the MCC staff. Before enrollment began, an
inservice about the study was provided to appropriate staff
members at the MCC and the GCRC. The author attended MCC Chest
Tumor Center conferences to identify potential participants and
the afternoon clinics to meet with those potential participants
for recruitment and possible enrollment. Potential participants
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were provided with detailed written and oral information
regarding the study and an invitation to participate. Potential
participants were given ample opportunity to ask questions or
discuss the study with family or significant others.
Participants were asked to provide their written consent prior
to enrolling in the study.
Due to lack of consenting participants after 6 months of
recruitment, a revised protocol was submitted to the VCU IRB on
December 10, 2010 to allow for online recruitment of
participants and data collection via anonymous survey. The
survey, launched on Survey Monkey on February 25, 2011,
consisted of the same questionnaires to be administered to inperson participants. Approximately 75 potential web sites were
identified and contacted for permission to post a recruitment
advertisement and link to the survey. Five organizations
(American Cancer Society, Joan Gaetz Lung Cancer Foundation,
Kate MacIntyre Foundation, Lung Cancer Alliance, National Lung
Cancer Partnership) agreed to post the recruitment advertisement
and link. Online data collection began immediately after receipt
of IRB approval. This method of data collection does not provide
information regarding the number of respondents from each web
site.
Minority inclusion. Lung cancer is the second most
prevalent cancer in the United States in both men and women. It
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was anticipated that the participants selected for this study
would
be representative of those demographics. MCC is designated by
the National Cancer Institute as a Minority-based Clinical
Oncology Program institution, since its patient population is at
least 40% minorities. Participants of all ethnic and racial
backgrounds were recruited. No racial or ethnic differences in
symptoms were expected or noted. The intent was to recruit
minorities consistent with the accessible population. The
consent form was written in plain language with minimal use of
scientific or medical jargon; this is consistent with VCU IRB
requirements. Based on the characteristics of the patient
population of MCC, the targeted/planned distribution of
participants by gender and racial/ethnic groups is shown in
Table 6. It should be noted that the final sample did not
include Hispanic or Latino participants; nor did it include
Black or African American participants. All patients meeting
inclusion criteria were recruited and no patient was excluded
from the study based on gender or race/ethnicity. Children and
adolescents under the age of 21 were not included in this study
because the incidence of lung cancer in this age group is small
as compared to adults.
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Table 6. Targeted/Planned Enrollment
Ethnic Category

Sex/Gender
Females Males Total
Hispanic or Latino
1
1
2
Not Hispanic or Latino
27
31
58
Ethnic Category: Total of all Participants
28
32
60
Racial Category
Asian
1
1
2
Black or African American
9
12
21
White
18
19
37
Racial Category: Total of all Participants
28
32
60

Data collection and procedures. Due to lack of consenting
participants for in-person data collection, all data were
obtained via the anonymous online survey. The recruitment
advertisement, including the link to the survey, was posted on
the 5 consenting web sites. Participants accessed the survey
from those web sites. The link took them to the initial page
which included a brief description of the survey and an
invitation to participate. Clicking to begin the survey
constituted consent to participate. It is estimated that the
time to complete the survey was approximately 25 minutes. Time
estimates for self-report instruments were based on information
obtained in personal communication with Jeffrey M. Stanton,
Ph.D., Associate Dean for Research and Doctoral Programs in the
School of Information Studies at Syracuse University on May 14,
2008.)
Data and safety monitoring plan. Participation in the survey
was anonymous. No identifying information was collected. Review
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of the data occurred regularly in order to monitor protocol
compliance with inclusion/exclusion criteria and gender and
minority recruitment. No adverse events were anticipated and
none known to occur.
Data analysis plan.

Because symptom cluster research has been

described as a “new frontier,” it is a developing area of
research with no single accepted definition of “cluster” or
analysis methods. While the study was guided by the TOUS, we did
not test each conceptual linkage. In this study we
operationalized the cluster as a group of co-occurring symptoms
that have an adverse impact on a defined outcome, quality of
life and/or functional ability. To achieve the aims, several
analytic strategies were used. Descriptive statistics were used
to characterize the sample in terms of demographic variables
(gender, race/ethnicity, stage of disease, treatment modalities,
and prevalence and severity of each variable).
Specific aim 1: to examine the relationship between the
symptoms of dyspnea anxiety in patients with lung cancer.

To

achieve this aim, Pearson’s correlations were used to examine
the relationships between the variables.
Specific aim 2: to examine the relationships among the
symptoms of dyspnea, anxiety, and symptom cluster components
(depressive symptoms, fatigue, pain) in patients with lung
cancer. To achieve this aim, principal component analysis and
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exploratory factor analysis of standardized scores of each
instrument will be used to determine the number of components
that can account for variability in the measures; and to
determine the number of common factors influencing the measures
and the strength of the relationships between each factor and
each observed measure.
Specific aim 3: to examine the correlation between functional
ability and quality of life in patients with lung cancer. Simple
correlation analysis was used to validate the relationship
between these outcomes in this population.
Specific aim 4: to explore the relationships among the
symptoms of dyspnea, anxiety, and symptom cluster components
(depressive symptoms, fatigue, pain) in patients with lung
cancer and patients’ functional ability.

Regression analysis

was used to explore the relationships of the predictor variables
with the outcome, functional ability.
Specific aim 5. to explore the relationships among the
symptoms of dyspnea, anxiety, and symptom cluster components
(depressive symptoms, fatigue, pain) in patients with lung
cancer and patients’ quality of life. As with specific aim 4;
regression techniques were used to explore the relationships
among the predictor variables and quality of life.
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This strategy permitted examination of several important
components of the symptom model (intensity, prevalence,
frequency). Data were analyzed using SPSS version 19.0.
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Chapter 4
Findings
The purpose of the study was to examine selected
relationships among symptoms common to individuals with lung
cancer. The specific aims were:
1) To examine the relationship between the symptoms of dyspnea
and anxiety in patients with lung cancer.
2) To examine the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer.
3) To examine the correlation between functional ability and
quality of life in patients with lung cancer.
4) To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer and patients’
functional ability.
5) To explore the relationships among the symptoms of dyspnea,
anxiety, and symptom cluster components (depressive symptoms,
fatigue, pain) in patients with lung cancer and patients’
quality of life.
This chapter reports the findings of the statistical
analysis of the data. The following areas are included:
description of the sample, description of the study variables
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and results related to the research aims. The chapter concludes
with a summary of the study findings.
Descriptive Analysis
Sample Size
The final sample consisted of 51 participants. All
participants were recruited through the 5 websites which agreed
to post the recruitment advertisement. The participants
completed the questionnaires via online survey through Survey
Monkey. While a few potential participants were identified at
Massey Cancer Center and invited to participate, none chose to
do so.
Sample Demographic Data
The age range of the sample was 19-82 years, mean age 57.2
years (SD = 10.975). Regarding tobacco use, 12 (23.5%) reported
that they had never smoked; 2 (3.9%) reported that they
currently smoke; and 37 (72.5%) reported that they have quit
smoking. Eight (15.7%) of participants reported that they use
supplemental oxygen. Demographics of the sample are summarized
in Table 7. Co-morbidities, disease characteristics, and
treatments received are summarized in Table 8.
Missing Data
At completion of the study, there were some missing data
values due to participant non-response. There was no apparent
pattern to these omitted responses. From 1 to 3 responses were
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omitted randomly throughout the questionnaire. No substitutions
were made for those missing values and data analysis was
performed using the total number of responses for each question.
Table 7. Demographic Characteristics
Variable
Gender
Female
Male
Ethnicity*
Hispanic/Latino
Not Hispanic/Latino
Race
American Indian/Alaska Native
Asian
Native Hawaiian/other Pacific Islander
Black or African American
White/Caucasian
Education
Some high school or less
High school degree or equivalent (GED)
College or Professional degree
Graduate degree
Employment
Unemployed
Employed part-time
Employed full-time
Retired
Relationship
Divorced/separated
Living with a partner
Married
Single, never been married
Widowed
*missing data
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Count

Percentage

35
16

68.6
31.4

0
48

94.1

1
2
0
0
48

2.0
3.9
0
0
94.1

4
16
19
12

7.8
31.4
37.3
23.5

12
2
12
25

23.5
3.9
23.5
49.0

11
7
32
0
1

21.6
13.7
62.7
0
2.0

Table 8. Health Characteristics
Variable
Severe asthma
No
Yes
Missing data
Chronic obstructive pulmonary disease (COPD)
No
Yes
Missing data
Chronic fatigue syndrome
No
Yes
Missing data
Depression
No
Yes
Missing data
Chronic pain
No
Yes
Missing data
Stage of disease
1
2
3
4
Limited
Extensive
Missing data
Type
Small cell (limited or extensive above)
Non-small cell (stage 1-4 above)
Missing data
Type of treatments received
Targeted therapies (Tarceva, Avastin)
Clinical trials
Surgery
Radiation
Chemotherapy
Missing data
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Count

Percentage

3
47
1

5.9
92.2
1.9

13
37
1

25.5
72.5
1.9

7
43
1

13.7
84.3
1.9

14
35
2

27.5
68.6
3.9

9
40
2

17.6
78.4
3.9

9
4
16
16
3
1
2

17.6
7.8
31.4
31.4
5.9
2.0
3.9

3
45
3

5.9
88.2
5.9

14
7
25
25
40
1

27.5
13.7
49.0
49.0
78.4
1.9

Statistical Analysis
Results: Specific Aim #1
Specific aim #1 was to examine the relationship between the
symptoms of dyspnea and anxiety in patients with lung cancer.
The maximum score on the Cancer Dyspnea Scale (CDS) is 48, with
higher scores indicating more severe dyspnea. The observed range
of scores was 0-36, mean 10.58. The State-Trait Anxiety
Inventory(STAI) provides a score for anxiety experienced “right
now’ (State) and a second score for anxiety experienced
generally (Trait). The possible range of scores on each is 2080, with higher scores indicating a higher level of anxiety. The
observed scores for State ranged from 33-62, mean 45.37. The
observed scores for Trait ranged from 34-58, mean 43.93. To
achieve this aim, Pearson’s two-tailed correlations were used to
examine the relationship between the variables. Dyspnea was
observed to be positively correlated with anxiety in both State
(r = 0.885) and Trait (r = 0.737).
Results: Specific Aim #2
Specific aim #2 was to examine the relationships among the
symptoms of dyspnea, anxiety, and symptom cluster components
(depressive symptoms, fatigue, pain) in patients with lung
cancer. Descriptive statistics for dyspnea and anxiety are
reported above. Depressive symptoms were measured using the
Center for Epidemiological Studies Depression (CES-D) Scale. The
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range of possible scores is 0-60, with high scores indicating
high levels of distress. The observed range of scores on the
CES-D was 0-46, mean 15.95. Fatigue was measured using the Brief
Fatigue Inventory (BFI), a tool which measures both the severity
of fatigue and its impact on daily functioning in the past 24
hours. A worst fatigue score >/= 7 indicates severe fatigue. The
observed scores for fatigue severity ranged from 0-10, mean
6.25. Observed global fatigue scores ranged from 0-9.78
(possible range 1-10) with a mean global fatigue score of 4.95.
Pain was measured using the Brief Pain Inventory (BPI), which
measures both severity of pain and its interference with daily
activity. There is no scoring algorithm, but the mean of the 4
severity items are used as a measure of pain severity and the
mean of the 7 interference items is used as a measure of pain
interference. Possible range on both scores is 0-10. The
observed severity score ranged from 1-6, mean 3.47. Scores of 14 are considered to be mild pain and scores of 5-6 are
considered to be moderate pain. The observed interference scores
ranged from 1-9.57, mean 3.59. To achieve this aim, principal
component analysis and exploratory factor analysis (KMO=.650;
Bartlett’s=160.386, df 28)were used to determine the number of
components that could account for variability in the measures,
and to determine the number of common factors influencing the
measures and the strength of the relationships between each
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factor and each observed measure. Correlations among the
variables are summarized in Table 9. Total variance explained by
these components, with Eigenvalues, is summarized in Table 10.
Table 9. Correlation Matrix
Pain
Dyspnea Anxiety Anxiety Depressive Severe Global Pain
State
Trait
Symptoms Fatigue Fatigue Severity interference
Dyspnea
1.000
.024
-.053
.578
.440
.622
.442
.758
Anxiety state
.024
1.000
.421
.000
-.089
-.047
-.094
-.183
Anxiety trait
-.053
.421
1.000
-.024
-.354
-.294
-.257
-.216
Depressive s/s
.578
.000
-.024
1.000
.422
.678
.314
.705
Severe fatigue
.440
-.089
-.354
.422
1.000
.869
.637
.564
Global fatigue
.622
-.047
-.294
.678
.869
1.000
.602
.795
Pain severity
.442
-.094
-.257
.314
.637
.602
1.000
.675
Pain interference
.758
-.183
-.216
.705
.564
.795
.675
1.000

Table 10. Total Variance Explained
Component
Initial Eigenvalues
Extraction Sums of Squared
Loadings
Total % of
Cumulative Total % of
Cumulative
Variance
%
Variance
%
Dyspnea
4.165 52.065
52.065
4.165 52.065
52.065
Anxiety state 1.447 18.085
70.151
1.447 18.085
70.151
Anxiety trait
.827 10.336
80.486
Depressive
.578 7.222
87.708
s/s
Severe
.465 5.819
93.527
fatigue
Global
.346 4.324
97.850
fatigue
Pain severity .134 1.677
99.527
Pain
.038 .473
100.000
interference

Rotation Sums of
Squared Loadings
Total
4.117
1.648

In this study, the scree plot supported a 2-factor solution due
to the “elbow” position at the second component Eigenvalue (see
Figure 3).
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Figure 3. Scree Plot
Results: Specific Aim #3
Specific aim #3 was to examine the correlation between
functional ability and quality of life in patients with lung
cancer. Functional ability was measured using the Duke Activity
Status Index (DASI), which measures functional capacity based on
the ability to perform common activities of daily living. The
possible range of scores is 0-58.2, with higher scores
indicating higher level of function. The range of observed
48

scores was 12-24, mean 15.88. Quality of life was measured using
the Functional Assessment of Cancer Therapy – Lung (FACT-L)
Scale, which provides a global score of health-related quality
of life. The possible range of scores is 0-136, with higher
scores indicating a better quality of life. The range of
observed was 34-77, mean 63.65. To achieve this aim, simple
correlation analysis was used to validate the relationship
between these outcomes in this population. A weak correlation
was observed between these components (r = -.175).
Results: Specific Aim #4
Specific aim #4 was to explore the relationships among the
symptoms of dyspnea, anxiety, and symptom cluster components
(depressive symptoms, fatigue, pain) in patients with lung
cancer and patients’ functional ability.
To achieve this aim, regression analysis was used to
explore the relationships of the predictor variables with the
outcome, functional ability. Because no strong correlation was
found between the outcome and any single predictor variable (see
Table 11), forward stepwise regression techniques were used.
While all correlations were weak to moderate, predictor
variables were added to the model from most to least
significant. Reliability statistics for the instruments are
summarized in Table 12.
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Table 11. Correlations – Predictor Variables/Functional Ability
FA
Dyspnea
.048
Depressive symptoms -.230
Severe fatigue
.049
Global fatigue
-.020
Pain severity
.040
Pain interference
-.012
Anxiety state
.277
Anxiety trait
.337

Table 12. Reliability Statistics in This Study
Instrument
Cronbach’s Alpha
Cancer Dyspnea Scale (CDS)
.782
State/Trait Anxiety Inventory (STAI)
.659
State domain
.503
Trait domain
.454
Center for Epidemiological Studies Depression Scale (CES-D)
.959
Brief Fatigue Inventory
.939
Brief Pain Inventory
.405
Severity
.904
Interference
.956
Duke Activity Status Index (DASI)
.850
Functional Assessment of Cancer Therapy-Lung (FACT-L)
.573
Physical domain
.880
Social/family domain
.849
Emotional domain
.737
Functional domain
.904
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Two models were tested; results are summarized in Table 13.
Table 13. Coefficients of Regression Models-Functional Ability

Standardized
Unstandardized Coefficients
Model
1

2

B
(Constant)

Std. Error
13.170

1.271

Dyspnea Score

.093

.083

CESD Adjusted

-.003

Severe Fatigue

Coefficients
Beta

t

Sig.

10.358

.000

.298

1.110

.278

.056

-.015

-.054

.958

.156

.451

.163

.345

.733

Global Fatigue Score

.069

.661

.064

.105

.918

Pain Severity

.001

.504

.001

.003

.998

Pain Interference

.127

.528

.113

.241

.812

25.927

4.417

5.870

.000

Dyspnea Score

.170

.068

.547

2.503

.020

CESD Adjusted

.014

.045

.070

.319

.753

Severe Fatigue

-.273

.367

-.285

-.745

.464

Global Fatigue Score

.741

.543

.685

1.364

.186

Pain Severity

.415

.405

.241

1.023

.317

Pain Interference

-.728

.460

-.646

-1.584

.128

STAI State

-.313

.079

-.652

-3.977

.001

STAI Trait

.031

.088

.057

.353

.728

(Constant)

a. Dependent Variable: Functional Ability
Model 1: r2 = .289, F change 1.629, p = .183
Model 2: r2 = .604, F change 8.735, p = .002

Results: Specific Aim #5
Specific aim #5 was to explore the relationships among the
symptoms of dyspnea, anxiety, and symptom cluster components
(depressive symptoms, fatigue, pain) in patients with lung
cancer and patients’ quality of life.
To achieve this aim, regression analysis was used to
explore the relationships of the predictor variables with the

51

outcome, quality of life. Because no strong correlation was
found between the outcome and any single predictor variable (see
Table 14), forward stepwise regression techniques were used.
While all correlations were weak to moderate, predictor
variables were added to the model from most to least
significant.
Table 14. Correlations – Predictor Variables/Quality of Life
QoL
Dyspnea
.048
Global fatigue
-.020
Anxiety state
.277
Pain interference
-.012
Severe fatigue
.049
Pain severity
.040
Depressive symptoms -.230
Anxiety trait
.337

Eight models were tested and results summarized in Table
15.
Table 15. Coefficients of Regression Models-Quality of Life

Standardized
Unstandardized Coefficients
Model
1

B
(Constant)
Dyspnea Score

2

(Constant)
Dyspnea Score
Global Fatigue Score

3

(Constant)
Dyspnea Score
Global Fatigue Score
STAI State

Std. Error
63.065

2.967

.055

.212

64.063

4.205

.114

.276

-.327

.960

41.957

15.596

.086

.271

-.217
.482
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Coefficients
Beta

t

Sig.

21.254

.000

.260

.797

15.236

.000

.099

.412

.683

-.082

-.341

.736

2.690

.012

.075

.319

.752

.944

-.054

-.230

.820

.328

.272

1.470

.153

.048

Table 15. continued
4

(Constant)

40.574

16.687

2.431

.022

.032

.341

.028

.095

.925

-.432

1.251

-.108

-.345

.733

STAI State

.513

.354

.290

1.451

.159

Pain Interference

.440

1.640

.106

.268

.791

33.872

17.496

1.936

.064

.024

.338

.021

.071

.944

-2.787

2.342

-.699

-1.190

.245

.609

.360

.344

1.690

.103

Pain Interference

1.268

1.771

.305

.716

.480

Severe Fatigue

1.782

1.503

.505

1.186

.247

33.108

17.896

1.850

.077

-.006

.352

-.006

-.018

.986

-3.284

2.680

-.823

-1.225

.232

.643

.376

.363

1.710

.100

Pain Interference

1.851

2.304

.446

.803

.430

Severe Fatigue

2.228

1.884

.632

1.183

.248

Pain Severity

-.831

2.053

-.131

-.405

.689

31.330

17.067

1.836

.079

.000

.336

.000

.000

1.000

-1.821

2.670

-.457

-.682

.502

.715

.360

.404

1.987

.059

Pain Interference

2.997

2.279

.722

1.315

.201

Severe Fatigue

1.673

1.818

.474

.920

.367

-1.682

2.007

-.266

-.838

.411

CESD Adjusted

-.409

.219

-.545

-1.863

.075

(Constant)

6.186

20.683

.299

.768

Dyspnea Score

-.045

.318

-.039

-.141

.889

-1.169

2.545

-.293

-.459

.650

.438

.369

.248

1.188

.247

Pain Interference

2.942

2.153

.708

1.366

.186

Severe Fatigue

1.792

1.719

.508

1.043

.308

-1.541

1.898

-.244

-.812

.425

-.476

.210

-.636

-2.267

.034

.797

.411

.399

1.941

.065

Dyspnea Score
Global Fatigue Score

5

(Constant)
Dyspnea Score
Global Fatigue Score
STAI State

6

(Constant)
Dyspnea Score
Global Fatigue Score
STAI State

7

(Constant)
Dyspnea Score
Global Fatigue Score
STAI State

Pain Severity

8

Global Fatigue Score
STAI State

Pain Severity
CESD Adjusted
STAI Trait
a. Dependent Variable: QL Total Score
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Model 1: r2 = .002, F change .068, p = .797
2
Model 2: r = .006, F change .116, p = .736
Model 3: r2 = .080, F change 2.160, p = .153
2
Model 4: r = .083, F change .072, p = .791
Model 5: r2 = .131, F change 1.406, p = .247
2
Model 6: r = .137, F change .164, p = .689
Model 7: r2 = .250, F change 3.471, p = .075
2
Model 8: r = .360, F change 3.767, p = .065
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Chapter 5
Discussion and Conclusions
Discussion
The Theory of Unpleasant Symptoms provided the theoretical
underpinnings for this study. The model suggests that several
symptoms can occur together and that the symptom experience may
be influenced by psychological and situational factors as well
as the physiological factors inherent in the disease process.
Based on this theory, a research model was developed to examine
the relationships among symptoms common to individuals with lung
cancer. Chapter 5 explores the results of the statistical
analyses described in the previous chapter and discusses
implications for further research and practice. Strengths and
limitations of the study are acknowledged and recommendations
for future research are proposed.
Conclusions
Specific aim #1. Specific aim #1 was to examine the
relationship between the symptoms of dyspnea and anxiety in
patients with lung cancer. Statistical analysis of the data
indicates a strong positive correlation between the symptoms of
dyspnea and anxiety (both anxiety in general and anxiety at the
time the survey was completed). The prevalence of dyspnea in
lung cancer patients is well documented. Graves et al.29 report a
prevalence of 52.7% in their study of 333 lung cancer patients
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and Joyce et al.30 report that it may be as high as 87%
regardless of stage of disease. Grave et al.29 also reported a
clinically significant level of anxiety in 62.4% of study
participants. Bruera et al.3, in their study of the frequency and
correlates of dyspnea in cancer patients, found a strong
correlation between dyspnea and anxiety in this population.
However, the correlation is difficult to interpret since anxiety
may be caused by dyspnea, or it may be a contributing factor to
dyspnea. Henoch et al.6, in a study to describe the symptom
experience of patients with lung cancer, found dyspnea to be a
complex experience comprised of both physical and psychological
aspects with significant correlations between anxiety and the
dimensions of dyspnea as measured using the CDS.
Specific aim #2. Specific aim #2 was to examine the
relationships among the symptoms of dyspnea, anxiety, and
symptom cluster components (depressive symptoms, fatigue, pain)
in patients with lung cancer. The mean score on the CES-D scale
for depression was 15.95, observed range 0-46. This is high, as
the reportable score for clinically significant depressive
symptoms is 16. It is noteworthy that 68.6% of participants
self-reported receiving a diagnosis of depression in their
medical history.
The strongest correlations observed among the variables
were between severe fatigue and global fatigue (r=.869), between
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global fatigue and pain interference (r=.795), and between
dyspnea and pain interference (r=.758). Anxiety showed only a
weak correlation with any of the other variables in the proposed
symptom cluster (depressive symptoms, fatigue, pain). There were
moderately significant positive correlations among depressive
symptoms, global fatigue, and pain interference (r=.678 and
r=.705, respectively); supporting the operational definition of
the symptom cluster as composed of these three symptoms.
Research of symptom clusters in patients with lung cancer
has been minimal, and a definitive cluster has yet to be
identified. Brown et al.92 found a 5-symptom cluster (fatigue,
shortness of breath, cough, pain, anorexia) in their study of
women with lung cancer. In that study, pain was identified as a
sentinel symptom, i.e. women who had pain were more likely to
have the 5-symptom cluster. Cheung, Le, and Zimmerman93 studied
symptom clusters in patients with advance cancers and identified
two distinct clusters. One cluster included fatigue, drowsiness,
nausea, decreased appetite, and dyspnea. The second cluster
included anxiety and depression. The sample in their study
included patients with various primary cancer sites (most
commonly gastrointestinal, lung, and breast). The elements of
the identified cluster varied by disease site, but certain
symptoms were consistent by cancer site. Notably, anxiety and
depression were clustered for all solid tumors93. Fox and Lyon13,
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in a secondary analysis of data obtained from 51 participants,
found evidence to support a 2-symptom cluster of depression and
fatigue in lung cancer survivors. Graves et al.29 reported that
the symptoms of depression, anxiety, pain, and fatigue were
predictive of distress in their study of lung cancer patients.
They found no association between level of distress and stage of
disease or type of treatment.
Specific aim #3. Specific aim #3 was to examine the
correlation between functional ability and quality of life in
patients with lung cancer. Simple correlation analysis showed
only a weak correlation between functional ability and quality
of life. The mean score of 15.88 out of a possible range of 058.2 would indicate that the study participants have a
relatively low level of functioning. Their disease has reduced
their ability to perform such routine activities as walking,
housework, and recreational sports. The mean quality of life
score, 63.65 out of a possible range of 0-136 would indicate
that the participants are experiencing diminished quality of
life. These individuals report a negative impact on their
quality of life in physical, social/family, emotional, and
functional domains. Lack of energy interferes with their ability
to meet the needs of their families and they are often forced to
spend time in bed. They are unable to enjoy time with friends
and family as they once did, putting a strain on relationships.
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They have feelings of sadness and worry about their illness,
their future, and their ability to cope. They are no longer able
to pursue their careers or recreational activities.
It is possible that the study sample was not large enough
to detect a significant correlation between functional ability
and quality of life. It is also possible that this finding may
be due to a change in the interpretation of the construct of
quality of life for these patients. Bernhard et al.77, studying a
group of patients with colon cancer, tested the hypothesis that
the meaning of quality of life for these patients would change
across different phases of the disease. They found that the
relative importance of domains such as functional ability and
energy level to quality of life had substantially changed for
these individuals as a result of their disease.
Specific aim #4. Specific aim #4 was to explore the
relationships among the symptoms of dyspnea, anxiety, and
symptom cluster components (depressive symptoms, fatigue, pain)
in patients with lung cancer and patients’ functional ability.
The first regression, which excluded both state and trait
anxiety, accounted for only 28.9% of the variance in functional
ability. The second model, which includes both state and trait
anxiety showed that, taken together, the predictor variables
accounted for 60.4% of the variance in functional ability (F
change = 8.735, p=.002).
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Specific aim #5. Specific aim #5 was to explore the
relationships among the symptoms of dyspnea, anxiety, and
symptom cluster components (depressive symptoms, fatigue, pain)
in patients with lung cancer and patients’ quality of life.
Of the 8 models tested, none showed a significant effect on
the dependent variable, quality of life. However, two models
accounted for a moderate percentage of explained variance in
QOL. Model 7, which included dyspnea, global fatigue, state
anxiety, pain interference, severe fatigue, pain severity, and
depressive symptoms, accounted for 25% of the variance in
quality of life (F change = 3.471, p=.075). Model 8, which
included dyspnea, global fatigue, state anxiety, pain
interference, severe fatigue, pain severity, depressive
symptoms, and trait anxiety, accounted for 36% of the variance
in quality of life (F change = 3.767, p=.065).
Symptom Clusters
In this study, a cluster of fatigue and pain, but not
depressive symptoms, in the presence of dyspnea and a persistent
high level of anxiety accounted for 60.4% of the reduction in
functional ability of the participants. Though not statistically
significant in this sample, this does provide evidence of the
co-occurrence of common symptoms in this population and warrants
further study. A cluster of depressive symptoms, fatigue and
pain, in the presence of dyspnea and persistent anxiety,
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accounted for 36% of the reduction in perceived quality of life.
While this is only a moderate percentage, it is evidence that
there is a clustering of symptoms that have significant
relationships with each other; and that together these symptoms
have a synergistic impact on quality of life. The results of
this study support the existence of the proposed symptom cluster
(depressive symptoms, fatigue, and pain) and provide evidence
that the cluster may also include dyspnea and anxiety in this
population.
The definition of a symptom cluster has yet to be defined.
It may be as simple as a nonrandom association of 2 or more
symptoms present at a single point in time45. A more stringent
definition requires that >75% of the proposed symptoms within a
cluster be present, and that the sentinel, or most prevalent,
symptom has to be present43.
Components of symptom clusters in individuals with cancer
vary across studies58. This may be partly due to differences in
the instruments used, the study design and statistical methods
used, and characteristics of the sample43. These differences
influence the composition of the clusters identified and make
comparisons among studies difficult to interpret. Paindepression-fatigue is among the commonly recognized clinical
clusters94. Functional ability and quality of life have been
identified as major clinical outcomes that are negatively

61

correlated with the number and/or severity of symptoms within
the symptom cluster13,95,96,97. A number of studies have provided
evidence that symptom clusters negatively impact the functional
ability and quality of life of the individual with cancer. So,
et al.96, in a multicenter study exploring a symptom cluster of
fatigue, pain, anxiety, and depression on quality of life in
women with breast cancer, found that the symptom cluster
components explained 60% of the variance associated with quality
of life. That is, women with higher levels of these symptoms
were more likely to perceive a lower quality of life. Fox and
Lyon13, reported that higher levels of fatigue and depression,
but not pain, were significantly correlated with lower quality
of life. In that study, fatigue was the most intense symptom and
was correlated with both depression and pain. The symptom
cluster of fatigue and pain in the Fox and Lyon study explained
29% of the variance in quality of life and provides evidence
supporting the presence of a symptom cluster for individuals
with lung cancer.
In addition to their negative effects on the psychological
well-being of individuals with cancer, these clusters of
symptoms also have detrimental affects on physical functioning.
Certain symptom clusters, particularly fatigue-pain, appear to
exert greater adverse effects on functional status than others51.
Karabulu et al.98, in a study to characterize the prevalence and
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severity of symptoms in a sample of 287 patients with cancer and
to describe the clustering of symptoms, reported that the most
common symptoms included fatigue, sadness, pain, distress, and
difficulty walking. Barsevick et al.46 reported that functional
status decreased and fatigue and depressive symptoms increased.
In keeping with the theoretical underpinnings of this
study, multiple studies have provided evidence that there may be
indirect associations among the symptoms in a symptom cluster.
Barsevick et al.46 tested the effect of functional status on the
relationship between depression and fatigue. Their mediation
hypothesis was supported; higher level of fatigue with poorer
functional status was associated with a higher level of
depressive symptoms. They proposed that functional status is a
mediator between depressive symptoms and fatigue. Direct and
indirect associations among fatigue, pain, and depressive
symptoms have been explored and analyses have shown only a
moderate correlation between pain and depressive symptoms99. So,
the relationship between fatigue and pain may not be independent
of emotional status. Depressive symptoms and/or anxiety might
mediate the relationship between fatigue and pain in some way.
The total impact of a symptom cluster may be greater than the
sum of the impact of the individual symptoms94.
We have yet to reach a consensus on the definition of a symptom
cluster or to identify disease specific symptom clusters. The
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stability of a symptom cluster over time is as yet unknown and
there is conflicting evidence regarding this question94. Gift et
al.41,48 reported that clusters remained stable over a 6-month
follow up period in patients with lung cancer and in a study of
symptom clusters in elderly patients with lung cancer. In
contrast, other studies56,100,101 have shown that the symptom
cluster can change with disease state and over time.
Summary
A strong positive correlation was found between dyspnea and
anxiety (both anxiety in general and anxiety at the time the
survey was completed). It is unclear whether anxiety is caused
by dyspnea, or if anxiety is a contributing factor to the
experience of dyspnea in lung cancer patients. While results of
this study cannot provide conclusive evidence of the existence
of a symptom cluster composed of depressive symptoms, fatigue,
and pain, the results are consistent with other studies in this
area. Significant positive correlations among these three
symptoms indicate that this is a possible symptom cluster
experienced by lung cancer patients in general.
Strengths and Limitations
A major strength of this study is the theoretical framework,
which provided a sound conceptual basis for the research model
developed to examine the study variables. Another strength is
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the use of sound and proven instruments to compile the survey
questionnaire.
There are several limitations to the study, most notably
the small sample size. Post hoc power analysis showed that this
study had 71% power, so it is possible that significant
relationships do exist but were not found. A larger sample might
have revealed more significant relationships, particularly
between functional ability and quality of life (Specific Aim
#3). A larger sample might also have revealed more significant
relationships among the predictor variables (dyspnea, anxiety,
and symptom cluster components of fatigue, depressive symptoms,
and pain) and the outcome variables functional ability and
quality of life, providing stronger evidence of the existence of
this symptom cluster (Specific Aims #4 and #5). Another
limitation is the total dependence on data collected via online
survey. In-person interviews would provide the opportunity to
ensure that participants understood the questions and,
therefore, increase confidence in the full accuracy of their
answers. Access to medical records would provide the opportunity
to verify self-reports of clinical diagnoses in the medical
history.
Recommendations for Future Research
This study provides further evidence of the complex nature
of the symptom experience in patients with lung cancer. It
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contributes to our understanding of the underlying mechanisms of
the proposed cluster of symptoms (depressive symptoms, fatigue,
pain) in individuals with lung cancer and the potential
synergistic effects among these symptoms. It provides
preliminary data on how these symptoms are related and how they
affect functional ability and quality of life in patients with
lung cancer. Further study is needed using larger samples and
in-person data collection to better understand the symptom
experience of these individuals in order to develop robust
interventions targeting effective symptom management.
Additionally, longitudinal studies would provide insight into
whether the components of the symptom cluster, and its influence
on functional ability and quality of life, change with disease
stage. As the length of the survivorship period increases, it is
critical that we establish universally accepted assessment tools
and statistical methods to gain a comprehensive understanding of
the symptom cluster that may be unique to individuals with
cancer.
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Appendix A
Informed Consent

First Page of Online Survey*
You are invited to participate in a research study examining
common symptoms experienced by lung cancer patients (discomfort
in breathing, anxiety, depressive symptoms, fatigue, and pain)
and how these symptoms affect quality of life and ability to
perform routine daily activities. If you choose to participate
you will be asked to complete an online survey that takes about
20 minutes. You are eligible to participate in this study if you
are age 21 or older and have been diagnosed with lung cancer.
There are no costs for participating other than the time you
spend completing the survey. No information will be collected
that will reveal your identity. If you would like to participate
in this study, please click on the “next” button below.

*Clicking on the link provided in the advertisement placed on
web sites took the potential participant to this page. Clicking
on the “next” button constituted informed consent to participate
in this study.
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Appendix B
Survey Materials

Summary of Questions in Online Survey

Domain

Demographics
Tobacco use history
Co-morbidities
Medication regimen/
Disease-specific
Dyspnea
Anxiety at time of data
collection (state)
Anxiety – general
tendency to be anxious
(trait)
Depressive symptoms

None

Items on
Data
Collection
Form
#1-7

None

#8-10

None

#11

None

#12-15

Cancer Dyspnea Scale (CDS)
State-Trait Anxiety Inventory
(STAI)
State-Trait Anxiety Inventory
(STAI)

#16-27
#28-47

Center for Epidemiologic
Studies Depression Scale
(CES-D)
Brief Fatigue Inventory (BFI)
Brief Pain Inventory (BPI)
Functional Assessment of
Cancer Therapy-Lung (FACTL)
Duke Activity Scale Index

#68-87

Properties

Scale or Index

Based on a review
of the literature
Based on a review
of the literature
Based on a review
of the literature
Based on a review
of the literature
12-items
20-items
20-items

20-items

Fatigue
Pain
Quality of life

9-items
9-items
36-items

Functional ability

12-items
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#48-67

#88-91F
#92-100G
#101-136

#137-148

Content of Online Survey

1. Age (years, last birthday) __________
2. Gender (F=female; M=male)________
3. Ethnicity (check one)
Hispanic/Latino
Not Hispanic/Latino
4. Race (check one)
American Indian/Alaska Native
Asian
Native Hawaiian or Other Pacific Islander
Black or African American
White/Caucasian
5. Education (check highest level completed)
Some high school or less
High school diploma or equivalent (GED)
College or Professional degree
Graduate degree
6. Employment (check current status)
Unemployed
Employed part-time
Employed full-time
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Retired

7. Relationship (check current status)
Divorced/Separated
Living with a partner
Married
Single, never been married
Widowed
8. Tobacco use (check all that apply)
Never smoked
Currently smoke (answer question #9)
Quit smoking (answer question #10)

9. If you currently smoke;
How many cigarettes do you smoke per day? __________
How many years have you smoked?

__________

10. If you have quit smoking;
How many cigarettes did you smoke per day? __________
How many years did you smoke?

__________

How long ago did you quit?

__________

11. Medical history (check all conditions that you have been diagnosed with)
Severe asthma; date of diagnosis
Chronic obstructive pulmonary disease (COPD); date of diagnosis______
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Chronic fatigue syndrome; date of diagnosis __________
Depression; date of diagnosis __________
Chronic pain; date of diagnosis __________
12. Do you use supplemental oxygen?
No
Yes
13. Stage of disease: _________; date of diagnosis _____________
14. Histological type (small cell or non-small cell):_______________________________
15. Past treatment modalities (check all that apply)
Targeted therapies (i.e. Tarceva or Avastin)
Clinical Trials
Surgery
Radiation
Chemotherapy
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We would like to ask you about your breathlessness or difficulty in breathing. Please answer
each question by circling only the number that best describes the breathing difficulty that you felt
during the past few days. Base your response on your first impression.

16. Can you inhale easily?

Not
at all
1

A
little
2

17. Can you exhale easily?

1

18. Can you breathe slowly?

3

4

Very
much
5

2

3

4

5

1

2

3

4

5

19. Do you feel short of breath?

1

2

3

4

5

20. Do you feel breathing difficulty
accompanied by palpitations and
sweating?

1

2

3

4

5

21. Do you feel as if you are panting?

1

2

3

4

5

22. Do you feel such breathing difficulty
that you don’t know what to do about
it?

1

2

3

4

5

23. Do you feel your breath is shallow?

1

2

3

4

5

24. Do you feel your breathing may stop?

1

2

3

4

5

25. Do you feel your airway has become
narrower?

1

2

3

4

5

26. Do you feel as if you are drowning?

1

2

3

4

5

27. Do you feel as if something is stuck
in your airway?

1

2

3

4

5
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Somewhat Considerably

A number of statements which people have used to describe themselves are given below.
Read each statement and then circle the appropriate number to the right of the statement to
indicate how you feel right now, that is, at this moment. There are no right or wrong answers.
Do not spend too much time on any one statement; but give the answer which seems to
describe your present feelings best.
Not
at
all
1

28. I feel calm.

Somewhat Moderately
so
2

3

Very
much
so
4

29. I feel secure.

1

2

3

4

30. I am tense.

1

2

3

4

31. I feel strained.

1

2

3

4

32. I feel at ease.

1

2

3

4

33. I feel upset.

1

2

3

4

34. I am presently worrying over possible

1

2

3

4

35. I feel satisfied.

1

2

3

4

36. I feel frightened.

1

2

3

4

37. I feel comfortable.

1

2

3

4

38. I feel self-confident.

1

2

3

4

39. I feel nervous.

1

2

3

4

40. I am jittery.

1

2

3

4

41. I feel indecisive.

1

2

3

4

42. I am relaxed.

1

2

3

4

43. I feel content.

1

2

3

4

44. I am worried.

1

2

3

4

45. I feel confused.

1

2

3

4

46. I feel steady.

1

2

3

4

47. I feel pleasant.

1

2

3

4

misfortunes.
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A number of statements which people have used to describe themselves are given below.
Read each statement and then circle the appropriate number to the right of the statement to
indicate how you generally feel.
Almost Sometimes Often Almost
never
always
1
2
3
4

48. I feel pleasant.
49. I feel nervous and restless.

1

2

3

4

50. I feel satisfied with myself.

1

2

3

4

51. I wish I could be as happy as others seem to be.

1

2

3

4

52. I feel like a failure.

1

2

3

4

53. I feel rested.

1

2

3

4

54. I am “calm, cool, and collected”.

1

2

3

4

55. I feel that difficulties are piling up so that I cannot

1

2

3

4

1

2

3

4

57. I am happy.

1

2

3

4

58. I have disturbing thoughts.

1

2

3

4

59. I lack self-confidence.

1

2

3

4

60. I feel secure.

1

2

3

4

61. I make decisions easily.

1

2

3

4

62. I feel inadequate.

1

2

3

4

63. I am content.

1

2

3

4

64. Some unimportant thought runs through my head

1

2

3

4

1

2

3

4

66. I am a steady person.

1

2

3

4

67. I get in a state of tension or turmoil as I think over

1

2

3

4

overcome them.
56. I worry too much over something that really doesn’t
matter.

and bothers me.
65. I take disappointments so keenly that I can’t put
them out of my mind.

my recent concerns and interests.
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Please select the choice for each item below that best describes how you
felt over the past week:

68. I was bothered by things
that usually don’t bother
me.
69. I didn’t feel like eating, my
appetite was poor.
70. I felt that I could not shake
off the blues even with help
from my family and friends.
71. I felt that I was not as good
as other people.
72. I had trouble keeping my
mind on what I was doing.
73. I felt depressed.
74. I felt that everything I did
was an effort.
75. I felt hopeless about the
future.
76. I thought my life had been
a failure.
77. I felt fearful.
78. My sleep was restless.
79. I was unhappy.
80. I talked less than usual.
81. I felt lonely.
82. People were unfriendly.
83. I did not enjoy life.
84. I had crying spells.
85. I felt sad.
86. I felt that people disliked
me.
87. I could not get “going”.

Rarely or
none of
the time
(<1 day)
0

Some or a
little of the
time
(1-2 days)
1

Occasionally or a
moderate amount of
the time
(3-4 days)
2

Most or all
of the time
(5-7 days)

0

1

2

3

0

1

2

3

0

1

2

3

0

1

2

3

0
0

1
1

2
2

3
3

0

1

2

3

0

1

2

3

0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3

0

1

2

3
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3

Throughout our lives, most of us have times when we feel very tired or fatigued.
Have you felt unusually tired or fatigued in the last week?
Yes ____ No ____
88. Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your fatigue right NOW.
0
1
2
3
4
5
6
7
8
9
10
No
As bad as
fatigue
you can imagine
89. Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your USUAL level of fatigue during the past 24 hours.
0
1
2
3
4
5
6
7
8
9
10
No
As bad as
fatigue
you can imagine
90. Please rate your fatigue (weariness, tiredness) by circling the one number that
best describes your WORST level of fatigue during the past 24 hours.
0
1
2
3
4
5
6
7
8
9
10
No
As bad as
fatigue
you can imagine
91. Circle the one number that describes how, during the past 24 hours, fatigue has
interfered with your:
A. General activity
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

B. Mood
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

C. Walking ability
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

D. Normal work (includes both work outside the home and daily chores)
0
1
2
3
4
5
6
7
8
9
10
Does not interfere
Completely interferes
E. Relations with other people
0
1
2
3
4
Does not interfere

5

6

7

8
9
10
Completely interferes

F. Enjoyment of life
0
1
2
3
Does not interfere

5

6

7

8
9
10
Completely interferes

4
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92. Throughout our lives, most of us have had pain from time to time (such as minor
headaches, sprains, and toothaches). Have you had pain other than these everyday
kinds of pain today?
1. Yes
2. No
93. On the diagram, shade in the areas where you feel pain. Put an X on the area that
hurts the most.

94. Please rate your pain by circling the one number that best describes your pain at its
worst in the last 24 hours.
0
1
2
3
4
5
6
7
8
9
10
No
Pain as bad as
pain
you can imagine
95. Please rate your pain by circling the one number that best describes your pain at its
least in the last 24 hours.
0
1
2
3
4
5
6
7
8
9
10
No
Pain as bad as
pain
you can imagine
96. Please rate your pain by circling the one number that best describes your pain on
the average.
0
1
2
3
4
5
6
7
8
9
10
No
Pain as bad as
pain
you can imagine
97. Please rate your pain by circling the one number that tells how much pain you have
right now.
0
1
2
3
4
5
6
7
8
9
10
No
Pain as bad as
pain
you can imagine
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98. What treatments or medications are you receiving for your pain?
__________________________________________________________________
99. In the past 24 hours, how much relief have pain treatments or medications
provided? Please circle the one percentage that most shows how much
relief you have received.
0%
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No
Complete
Relief
Relief
100. Circle the one number that describes how, during the past 24 hours, pain has
interfered with your:
A. General activity
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

B. Mood
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

C. Walking ability
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

D. Normal work (includes both work outside the home and housework)
0
1
2
3
4
5
6
7
8
9
10
Does not interfere
Completely interferes
E. Relations with other people
0
1
2
3
4
Does not interfere

5

6

7

8
9
10
Completely interferes

F. Sleep
0
1
2
Does not interfere

3

4

5

6

7

8
9
10
Completely interferes

G. Enjoyment of life
0
1
2
3
Does not interfere

4

5

6

7

8
9
10
Completely interferes
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Below is a list of statements that other people with your illness have said are important. By
circling one (1) number per line, please indicate how true each statement has been for
you during the past 7 days.
Not
at all
0

PHYSICAL WELL-BEING
101. I have a lack of energy.

A little Somewhat
bit
1
2

Quite a
bit
3

Very
much
4

102. I have nausea.

0

1

2

3

4

103. Because of my physical condition, I

0

1

2

3

4

104. I have pain.

0

1

2

3

4

105. I am bothered by side effects of

0

1

2

3

4

106. I feel ill.

0

1

2

3

4

107. I am forced to spend time in bed.

0

1

2

3

4

have trouble meeting the needs of my
family.

treatment.

Not
at
all
0

A
little
bit
1

Somewhat

Quite
a bit

Very
much

2

3

4

109. I get emotional support from my family.

0

1

2

3

4

110. I get support from my friends.

0

1

2

3

4

111. My family has accepted my illness.

0

1

2

3

4

112. I am satisfied with family communication

0

1

2

3

4

0

1

2

3

4

0

1

2

3

4

SOCIAL/FAMILY WELL-BEING
108. I feel close to my friends.

about my illness.
113. I feel close to my partner (or the person who
is my main support)
114. Regardless of your current level of sexual
activity, please answer the following question. If
you prefer not to answer it, please check this box
 and go to the next section.

I am satisfied with my sex life.
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By circling one (1) number per line, please indicate how true each statement has been for
you during the past 7 days.

EMOTIONAL WELL-BEING

2

Quite a
bit
3

Very
much
4

1

2

3

4

0

1

2

3

4

118. I feel nervous.

0

1

2

3

4

119. I worry about dying.

0

1

2

3

4

120. I worry that my condition will get

0

1

2

3

4

Not at
all
0

A little
bit
1

Somewhat
2

Quite a
bit
3

Very
much
4

0

1

2

3

4

123. I am able to enjoy life.

0

1

2

3

4

124. I have accepted my illness.

0

1

2

3

4

125. I am sleeping well.

0

1

2

3

4

126. I am enjoying the things I usually do

0

1

2

3

4

0

1

2

3

4

115. I feel sad.
116. I am satisfied with how I am coping

Not at
all
0

A little
bit
1

Somewhat

0

with my illness.
117. I am losing hope in the fight against
my illness.

worse.

FUNCTIONAL WELL-BEING
121. I am able to work (include work at
home).
122. My work (include work at home) is
fulfilling.

for fun.
127. I am content with the quality of my
life right now.
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By circling one (1) number per line, please indicate how true each statement has been for
you during the past 7 days.

ADDITIONAL CONCERNS Not at all A little bit Somewhat Quite a bit Very much
128. I have been short of breath.
0
1
2
3
4
129. I am losing weight.

0

1

2

3

4

130. My thinking is clear.

0

1

2

3

4

131. I have been coughing.

0

1

2

3

4

132. I am bothered by hair loss.

0

1

2

3

4

133. I have a good appetite.

0

1

2

3

4

134. I feel tightness in my chest.

0

1

2

3

4

135. Breathing is easy for me.

0

1

2

3

4

136. Have you ever smoked?
No ___ Yes ___ If yes:
I regret my smoking

0

1

2

3

4
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Can You?
137. Take care of yourself, that is, eating, dressing, bathing or using the toilet?

Yes No

138. Walk indoors, such as around your house?

Yes No

139. Walk a block or two on level ground?

Yes No

140. Climb a flight of stairs or walk up a hill?

Yes No

141. Run a short distance?

Yes No

142. Do light work around the house like dusting or washing dishes?

Yes No

143. Do moderate work around the house like vacuuming, sweeping floors, or
carrying in groceries?

Yes No

144. Do heavy work around the house like scrubbing floors, or lifting or moving
heavy furniture?

Yes No

145. Do yard work like raking leaves, weeding, or pushing a power mower?

Yes No

146. Have sexual relations?

Yes No

147. Participate in moderate recreational activities like golf, bowling, dancing,
doubles tennis, or throwing a basketball or football?

Yes No

148. Participate in strenuous sports like swimming, singles tennis, football,
basketball or skiing?

Yes No

92

Appendix C
Advertisement Placed on Websites

Symptom Clusters in Lung Cancer Patients
 A research study approved by the Virginia Commonwealth University Institutional
Review Board (IRB).
You are invited to participate in a research study examining common symptoms experienced by
lung cancer patients (discomfort in breathing, anxiety, depressive symptoms, fatigue, and pain)
and how these symptoms affect quality of life and ability to perform routine daily activities. If you
choose to participate you will be asked to complete an online survey that takes about 20
minutes. You are eligible to participate in this study if you are age 21 or older and have been
diagnosed with lung cancer. There are no costs for participating other than the time you spend
completing the survey. No information will be collected that will reveal your identity.
If you would like to participate in this study, please click on the link below.

http://www.surveymonkey.com/s/BMZFLGZ
NOTE: If potential participants cannot click on the link from the posting please change “click on
the link below” to “copy and paste the link below into your browser”
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